257R-1

GCDFP-15 (EP1582Y) Rabbit Monoclonal Primary Antibody

• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: rabbit
• Quality Level: 100; 500
• conjugate: unconjugated
• antibody form: culture supernatant
• antibody product type: primary antibodies
• clone: EP1582Y, monoclonal
• description: For In Vitro Diagnostic Use in Select Regions (See Chart)
• form: buffered aqueous solution
• species reactivity: human
• packaging: vial of 0.1 mL concentrate (257R-14); vial of 0.5 mL concentrate (257R-15); bottle of 1.0 mL predilute (257R-17); vial of 1.0 mL concentrate (257R-16); bottle of 7.0 mL predilute (257R-18)
• manufacturer/tradename: Cell Marque^™
• technique(s): immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
• isotype: IgG
• control: breast, breast carcinoma
• shipped in: wet ice
• storage temp.: 2-8°C
• visualization: cytoplasmic
• Gene Information: human ... PIP(5304)

Description

General description

Gross cystic disease fluid protein-15 (GCDFP-15) is one of four major component proteins found in the cystic fluid obtained from patients with fibrocystic changes of the breast. GCDFP-15 is a marker of apocrine glandular differentiation in both benign and malignant mammary epithelium. This protein has a widespread distribution in apocrine glands elsewhere in the axillary and perianal tissues, as well as in the sublingual and submaxillary salivary glands. The GCDFP-15 protein is a 15 kDa glycoprotein shown to be prolactin-inducible, and the GCDFP-15 gene has been cloned. Ultrastructurally, the GCDFP-15 protein has been localized in Golgi vesicle and cytoplasmic granules. The protein is released by exocytosis at the apices of the mammary epithelial cells. The primary application for this antibody product is the identification of breast carcinoma in the metastatic setting, or fluid analysis. In a study by Wick et al. on paraffin sections of 105 breast cancers and 585 non-mammary malignancies in order to assess its value in this context, anti-GCDFP-15 was compared with another putative mammary epithelial marker, alpha-lactalbumin (ALA), with respect to sensitivity and specificity for a diagnosis of breast carcinoma. Overall, the rates of specificity and sensitivity and positive predictive value for GCDFP-15 were 95%, 74%, and 74%, respectively. A consistent congruency between the reactivity patterns of primary and metastatic breast cancers was noted for GCDFP-15. Besides mammary carcinomas, the major tumor types that express GCDFP-15 were carcinomas of the salivary glands and sweat glands. Since the latter two types of lesions are unlikely to be diagnosed as metastatic breast cancer, statistical indices were recalculated after exclusion of these three tumor types. Following this exclusion, the adjusted rate of specificity of GCDFP-15 and positive predictive value for a diagnosis of metastatic carcinoma of the breast were each 99%. Another study by Bhargava et al. has shown GCDFP-15 staining of a higher percentage of cancer cells in lobular carcinoma as compared to ductal carcinoma of the breast.

Linkage

GCDFP-15 Positive Control Slides, Product No. 257S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Storage Class Code: 12 - Non Combustible Liquids
• WGK: WGK 2
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable